Indiana University Hospital
Indianapolis, Indiana, 46202, United States
NCT Number: NCT03860051
The purpose of this study is to study the role of the enzyme (substance produced by the body that helps in a biochemical reaction like digestion in the body) responsible for digestion of lactose and the role of the gut bacteria (bacteria in the intestine) in producing symptoms of lactose intolerance.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Indianapolis, Indiana, 46202, United States
The study involves 3 visits and will include 2 types of subjects - those who have the the diagnosis of lactose intolerance (subjects) and those who do not have lactose intolerance (controls).
Visit 1:
In total, it is estimated that the research participation will add about 1 hour to your planned procedure visit. At Visit 1 following will be done
Visit 2:
Visit 2 will take approximately 6 hours to complete. If the subject returns for Visit 2, they will do the following
Visit 3:
Visit 3 will take approximately less than one hour to complete. For those who are interested in returning for Visit 3,
Participants who complete Aim 1 and meet further eligibility criteria for Aim 2 may be contacted by research staff to return for Visit 2 (breath test). Those who are agreeable to participating and are scheduled for Visit 2 will be instructed to consume a low-fiber meal and fast for 12 hours prior to their breath test. We will contact the participant 24 to 48 hours prior to the test day as a reminder to consume a low fiber meal and fast for 12 hours.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patient ages 18-75 presenting for upper gastrointestinal endoscopy for any indication except those outlined in the exclusion criteria below at the IU GI Endoscopy Sites including: IU North Hospital, Glen Lehman Endoscopy Suite, Springmill/Beltway Surgery Center, IU Saxony, and Eskenazi Hospital will be eligible for participation. Participants should be willing and able to sign informed consent.
Inclusion criteria
for Controls (Aim 1): Adult patients ages 18-75 years meeting basic eligibility criteria as listed above will be considered for inclusion. Participants should report no current or recent history of intolerance to and avoidance of dairy nor use of treatments and products for dairy intolerance.
Inclusion criteria
for Patients with Self-Reported Lactose Intolerance (Aim 1): Adult patients ages 18-75 years meeting basic eligibility criteria as listed above will be considered for inclusion. Participants should report current or recent history of intolerance to and avoidance of dairy.
Inclusion criteria
for Controls (Aim 2): All controls eligible for and completing Aim 1 will be considered eligible for inclusion. Participants should not meet any of the Aim 2 exclusion criteria.
Inclusion criteria
for Patients with Self-Reported Lactose Intolerance (Aim 1): All patients with self-reported lactose intolerance eligible for and completing Aim 1 will be considered eligible for inclusion. Participants should not meet any of the Aim 2 exclusion criteria.
Exclusion criteria
(Aim 1):
Exclusion criteria
(Aim 2):
Time frame: 1 day
Lactase activity (µmol/min/g) will be assessed from small bowel biopsy specimens
Time frame: 1 day
We will assess symptom severity using the lactose assessment tool
Time frame: 1 day
The small intestinal microbiome will be assessed by 16S allele PCR sequencing (16S) and Shotgun Metagenomic Sequencing (SGS)
Time frame: 1 day
Maldigestion status will be assessed by hydrogen breath test
Time frame: 1 day
The fecal microbiome will be assessed by 16S allele PCR sequencing (16S) and Shotgun Metagenomic Sequencing (SGS)
Indiana University
Other
Association Between Lactase Deficiency, Symptoms of Lactose Intolerance, and the Small Intestinal Microbiome in Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07652827
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Concepción, Chile
View Trial DetailsNCT07494123
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT06617364
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Erlangen, Bavaria, Germany
View Trial DetailsNCT06789068
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cairo, Egypt
View Trial Details